Approved & therapeutic
Lanreotide
Somatuline Depot
Lanreotide is a long-acting somatostatin analogue supplied as a supersaturated gel in a prefilled syringe, given by deep subcutaneous injection once every four weeks. It is approved for acromegaly, for gastroenteropancreatic neuroendocrine tumours, and for carcinoid syndrome.
Also known as: Somatuline, BIM 23014
- Status
- Lanreotide is approved by the U.S. FDA and has official prescribing information.
- Evidence
- Approved labeling. Official prescribing information exists, based on clinical trials in people.
- Half-life
- Apparent terminal elimination half-life of approximately 23 to 30 days from the depot formulation, reflecting slow release from the injection site rather than slow clearance of the molecule itself.
- How it's taken
- Deep subcutaneous injection into the superior external quadrant of the buttock
- Mechanism
- Other
- Pathways
- GH axis
How Lanreotide works
Like octreotide, lanreotide is a somatostatin analogue with strongest affinity for SSTR2 and SSTR5, suppressing growth hormone and a range of gut and pancreatic hormones. Its formulation as an aqueous gel rather than a microsphere depot is what produces the extended release profile without a separate reconstitution step.
What research has looked at
- In acromegaly, the label describes reduction of growth hormone and IGF-1 as the basis for approval.
- In unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumours, the CLARINET trial supported an indication to improve progression-free survival. This is a tumour-control indication, distinct from the symptom-control role of somatostatin analogues in carcinoid syndrome.
- In carcinoid syndrome it reduces the need for short-acting somatostatin analogue rescue therapy.
- Four-weekly dosing with a formulation that does not require reconstitution.
Evidence level: Approved labeling. Official prescribing information exists, based on clinical trials in people. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Cholelithiasis and gallbladder sludge, as with other somatostatin analogues; biliary obstruction and cholecystitis have been reported.
- Both hyperglycemia and hypoglycemia, reflecting simultaneous suppression of insulin and glucagon.
- Sinus bradycardia and other conduction abnormalities.
- Thyroid function suppression has been reported.
- Injection-site reactions, diarrhea, abdominal pain, nausea and headache are among the most frequent adverse reactions.
Sources
- FDA approved-drug listing for lanreotide · U.S. Food & Drug Administration
- DailyMed prescribing information for lanreotide · NIH · DailyMed
- PubMed research on lanreotide CLARINET neuroendocrine · NIH · National Library of Medicine
- DrugBank record for lanreotide · DrugBank
Track Lanreotide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Lanreotide FAQ
What is Lanreotide?
Lanreotide is a long-acting somatostatin analogue supplied as a supersaturated gel in a prefilled syringe, given by deep subcutaneous injection once every four weeks. It is approved for acromegaly, for gastroenteropancreatic neuroendocrine tumours, and for carcinoid syndrome.
How does Lanreotide work?
Like octreotide, lanreotide is a somatostatin analogue with strongest affinity for SSTR2 and SSTR5, suppressing growth hormone and a range of gut and pancreatic hormones. Its formulation as an aqueous gel rather than a microsphere depot is what produces the extended release profile without a separate reconstitution step.
Is Lanreotide FDA approved?
Yes. Lanreotide is approved by the U.S. FDA and has official prescribing information. Evidence level: approved labeling. Official prescribing information exists, based on clinical trials in people.
What is the half-life of Lanreotide?
Reported half-life: Apparent terminal elimination half-life of approximately 23 to 30 days from the depot formulation, reflecting slow release from the injection site rather than slow clearance of the molecule itself.
How is Lanreotide taken?
Deep subcutaneous injection into the superior external quadrant of the buttock.
What side effects have been reported with Lanreotide?
Reported in the sources: Cholelithiasis and gallbladder sludge, as with other somatostatin analogues; biliary obstruction and cholecystitis have been reported; Both hyperglycemia and hypoglycemia, reflecting simultaneous suppression of insulin and glucagon; Sinus bradycardia and other conduction abnormalities; Thyroid function suppression has been reported; Injection-site reactions, diarrhea, abdominal pain, nausea and headache are among the most frequent adverse reactions.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.